The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Innovation1 Biotech are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Innovation1 Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable fundamental drivers, Innovation1 Biotech is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Begin Period Cash Flow
137.5 K
Price Earnings Ratio
0.0406
Free Cash Flow
-3.1 M
Innovation1
Innovation1 Biotech Relative Risk vs. Return Landscape
If you would invest 0.02 in Innovation1 Biotech on November 13, 2025 and sell it today you would earn a total of 0.00 from holding Innovation1 Biotech or generate 0.0% return on investment over 90 days. Innovation1 Biotech is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than Innovation1, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Innovation1 Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Innovation1 Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Innovation1 Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Innovation1 Biotech generated a negative expected return over the last 90 days
Innovation1 Biotech has some characteristics of a very speculative penny stock
Innovation1 Biotech currently holds 554.4 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Innovation1 Biotech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation1 Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation1 Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation1 Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation1 to invest in growth at high rates of return. When we think about Innovation1 Biotech's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (40.88 M) with loss before overhead, payroll, taxes, and interest of (17 K).
Innovation1 Biotech currently holds about 636.16 K in cash with (3.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 75.0% of Innovation1 Biotech shares are held by company insiders
Innovation1 Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Innovation1 OTC Stock often depends not only on the future outlook of the current and potential Innovation1 Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Innovation1 Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding
20 M
Short Long Term Debt
10000.00
Shares Float
2 M
Innovation1 Biotech Fundamentals Growth
Innovation1 OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Innovation1 Biotech, and Innovation1 Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Innovation1 OTC Stock performance.
Assessing Innovation1 Biotech's fundamental ratios provides investors with valuable insights into Innovation1 Biotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Innovation1 Biotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Innovation1 Biotech Inc. operates as a small molecule drug discovery company. The company was founded in 2014 and is based in New York, New York. Innovation1 Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
Things to note about Innovation1 Biotech performance evaluation
Checking the ongoing alerts about Innovation1 Biotech for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Innovation1 Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Innovation1 Biotech generated a negative expected return over the last 90 days
Innovation1 Biotech has some characteristics of a very speculative penny stock
Innovation1 Biotech currently holds 554.4 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Innovation1 Biotech has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Innovation1 Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Innovation1 Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovation1 Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovation1 to invest in growth at high rates of return. When we think about Innovation1 Biotech's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (40.88 M) with loss before overhead, payroll, taxes, and interest of (17 K).
Innovation1 Biotech currently holds about 636.16 K in cash with (3.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 75.0% of Innovation1 Biotech shares are held by company insiders
Evaluating Innovation1 Biotech's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Innovation1 Biotech's otc stock performance include:
Analyzing Innovation1 Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Innovation1 Biotech's stock is overvalued or undervalued compared to its peers.
Examining Innovation1 Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Innovation1 Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Innovation1 Biotech's management team can help you assess the OTC Stock's leadership.
Pay attention to analyst opinions and ratings of Innovation1 Biotech's otc stock. These opinions can provide insight into Innovation1 Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Innovation1 Biotech's otc stock performance is not an exact science, and many factors can impact Innovation1 Biotech's otc stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Additional Tools for Innovation1 OTC Stock Analysis
When running Innovation1 Biotech's price analysis, check to measure Innovation1 Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Innovation1 Biotech is operating at the current time. Most of Innovation1 Biotech's value examination focuses on studying past and present price action to predict the probability of Innovation1 Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Innovation1 Biotech's price. Additionally, you may evaluate how the addition of Innovation1 Biotech to your portfolios can decrease your overall portfolio volatility.